Iclusig

Ponatinib, the active ingredient in Iclusig, is a tyrosine kinase inhibitor presented as a 15 mg and 30 mg tablet for oral use. It treats chronic myeloid leukemia and Philadelphia chromosome‑positive acute lymphoblastic leukemia that are resistant or intolerant to prior therapy, targeting the BCR‑ABL kinase including the T315I mutation.

GNH USA supplies Iclusig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with a focus on quality assurance, regulatory compliance and reliable global logistics, and timely delivery.

Ponatinib is indicated for hematologic malignancies driven by BCR‑ABL tyrosine‑kinase activity.

- Chronic myeloid leukemia (CML) resistant or intolerant to prior therapy: provides disease control when other tyrosine‑kinase inhibitors have failed. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL) resistant or intolerant to prior therapy: offers a targeted treatment option for patients with limited alternatives.

Ponatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypertension: elevated blood pressure that may require monitoring or medication. - Diarrhea: mild to moderate gastrointestinal upset. - Nausea: occasional feeling of sickness. - Rash: skin irritation or erythema.

Serious or Rare Side Effects: - Arterial occlusive events: risk of serious cardiovascular complications such as ischemia or thrombosis. - Pancreatitis: inflammation of the pancreas that can be severe. - Hepatotoxicity: significant liver enzyme elevations indicating possible liver injury.

Before initiating Ponatinib therapy, clinicians should consider several precautionary measures to minimize risk. - Cardiovascular monitoring: assess blood pressure and vascular health regularly. - Liver function: check hepatic enzymes before and during treatment. - Pancreatic enzymes: monitor amylase and lipase levels periodically. - Pregnancy: contraindicated; avoid use in pregnancy (Category D) and advise effective contraception. - Drug interactions: review concomitant medications for CYP3A4 inhibitors or inducers. - Store at ambient temperature: keep tablets below 25 °C in the original packaging, protected from moisture.

Ponatinib interacts with several medicines; understanding the interaction level guides clinical management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ponatinib exposure and toxicity. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce ponatinib effectiveness.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance bleeding risk. - Antiplatelet agents (e.g., aspirin): may exacerbate vascular events. - CYP3A4‑metabolized statins (e.g., simvastatin): may raise statin plasma levels.